The aim of this study was to establish the concentration of insulin-like growth factor-I (IGF-I) in saliva of acromegalic patients, and to compare it with the basal levels of serum IGF-I and growth hormone. IGF-I was determined in extracted serum or neat saliva by a disequilibrium RIA using antibodies and iodinated ligand from Amersham and WHO 87/518 s Standard. The detection limit of the assay was 0.5 μg/l, and the intra-and interi( assay coefficients of variations were 7.9% and 15% respectively. Our study included 13 healthy adult individuals i t and 17 acromegalics. Compared with healthy adult subjects, acromegalics had significantly higher salivary IGF-I i! concentrations (mean ± SEM 5.4 ± 2.64 vs. 10.5 +-5.69 μg/l; p < 0.01), s well s serum IGF-I (176 ± 42.9 vs. '* 520 ± 98.8 μg/l; p < 0.0001) and somatotropin levels (1.2 ± 1.02 vs. 15.4 ± 9.89 μg/l; p < 0.0001). However, 1 47.1% patients (8 put of 17) with active acromegaly had salivary IGF-I concentrations within the normal r nge, ί Serum IGF-I and somatotropin concentrations were found to follow more closely the disease activity after adenoj mectomy, compared with the concentrations of salivary IGF-I. These results suggest that the IGF-I levels in serum and saliva are somatotropin-dependent. According to our results, measurement of IGF-I in saliva cannot be considered s an additional ineasure for evaluation of the disease activity in acromegaly, being less reliable than the determination of IGF-I and somatotropin in serum.
Introduction
dence that IGF-I is present in salivary glands of rats and mice (6) . Circulating concentrations of IGF-I are dependent on the rate of growth hormone (somatotropin) secretion, being The present study was undertaken to establish the value low in hypopituitary and high in acromegalic patients (l, of IGF-I levels in the saliva of acromegalic patients and 2). Unlike insulin, IGF-I in the circulatioii (originatkg to compare it with serum IGF-I and somatotropin conmainly from liver), is bouad to specific binding proteins eentrations. (3) and consequentially present in much higher coneentrations.
Patients and Methods It has recently been reported (4, 5) that IGF-I in human p tients mixed saliva is present in the free form only and that i. codd * a good ««sure for pr««^ fte overaH somatotropin Status. Unlike lipophilic 'drugs or steroid males, aged 29-62 years, were admitted for examination and hormones, which are plasma ultrafdtrates, it is assumed studied after fiilly infonned oral consent had been obtained. All *t_ ^ ^ τκ-,τ-,· j · -i r> , ,· acromegalic patients had elevated basal somatotropin concentrathat the IGFs m saliva are denved from the sahvaiy tions ^ were not suppress ed be low 5 μδ Λ by an oral load of glands (4, 5) . There is also immunohistochemical evi-
lOOgofglucose. An indwelling teflon cannula was inserted tnme antecubital vein after overnight fasting at 8 a. m., and two basal blood samples vvere obtained at 8.30 and 9 a. m.; after clotting, the blood was centrifuged at 1500g, and the serum was kept frozen at -20 °C until analysed. Free flowing mixed saliva (5 ml) was then collected during a 30-min period, centrifuged for 10 rnin at 1500g at room temperatiire, and stored at -20 °C until analysis. Before RJA, thawed saliva was centrifuged again and a clear, non-viscous sample was analysed. Some samples needed f rther centrifugation to obtain a clear, non-viscous saliva.
Assays
Serum samples for IGF-I determination were extracted according to the method of Daughaday et al. (7), with some modifications. Briefly, 0.1 ml of serum were extracted with 0.4 ml acidic ethanol (2 mol/1 HC1, volume fraction 0.125, in absolute ethanol). After centrifugation, 0.2 ml of the supernatant were neutralized with 0.1 ml 0.684 mol/1 Tris. The mixture was centrifuged and 0.1 ml of the supernatant was finally diluted with 0.4 ml 0.025 mol/1 phosphate buffer, pH 7.6, with l g/l gelatine and 0.2 l NaN 3 (RIA buffer). In order to establish a sensitive and reliable method for IGF-I determination in serum and saliva, RIA was optimized with commercially available antibodies and iodinated ligand from Amersham International (UK), using a disequilibrium assay: 0. l ml of l : 37.5 diluted serum extract, pure mixed saliva or Standard (WHO 87/518) was.incubated with 0.1 ml of antibody solution (initial dilution of l \ 6400 in RIA buffer) at 4 °C for 24 h. After incubation, 0. l ml of iodinated IGF-I was added and the tubes were f rther incubated overnight for 16-18 h at 4 °C. Separation of the bound and free ligand was performed with 0.8 ml of cold (4 °C) 200 g/l PEG 6000 in 0.025 mol/1 phosphate buffer, pH 7.2, containing 0.2 g/l NaN 3 , and centrifuged for 30 min, 3000 g at 4 °C. This method of Separation was comparable with a more tedious one using dextran coated charcoal, s described by the manufacturer, giving non-specific binding of about 5%.
According to the manufacturer's data, cross reactivities of IGF-I antibodies with IGF-II and insulin s well s epidermal growth factor are negligible: crossreactivity with human IGF-II was < 0.5%, a 50% displacement of ligand gave the insulin concentration of 2000 mU/1, and 95.2 μg/l of epidermal growth factor did not differ from the Standard zero value. Intra-assay coefficients of Variation (CVs) for serum concentrations at 101, 273 and 540 μg/l (n = 20) were 6.4%, 4.0% and 5.7%, and for salivary concentrations at 2.99, 5.93 and 13.7 μg/l (n = 20) they were 7.9%, 5.3% and 6.7%, respectively. Interassay CVs for the same serum levels (n = 9) were 9.3%, 8.5% and 8.9%, and for salivary levels (n = 7) 15.0%, 10.2% and 9.9%, respectively. The Standard curve covered the r nge 0.48-62 μg/l ? with an assay detection limit of 0.5 μ §/1. The addition test, in which IGF-I Standard was added to serum or saliva, and the dilution test in which serum was diluted with saline and saliva with RIA buffer, produced lines that were parallel to the Standard curve. With this System, both serum (after extraction) and salivary IGF-I concentrations can be determined with the same RIA. Growth hormone was determined with a commercially available RIA test manufactured by Diagnostic Products Corporation (CA, USA). The test is calibrated against WHO 66/217, WHO 80/ 505 and National Institutes of Health (NIH), NIAMDD-hGH-RP-1. The assay detection limit was 0.5 μ §/1, and the intra-and interassay CVs were 6.9% and 8.4%, respectively.
The results of hormone determinations represent the rnean of duplicate determinations in blood collected at 9 a. m., or in mixed saliva. 
Results
With onr System, no detectable IGF-I eoncentrations could be demonstrated in the presence of biadmg proteins (e. g. serum), but we were able measure IGF-I concentrations in extracted serum pr neat saliva. Recovery of 125 I-labelled IGF-I added to serum was 99.9% ± 2.4% for normal, and 98.3% i 2.4% for acromegalic sera. Multiple centrifugations of saliva did not ffect salivary IGF-I concentrations. Salivary IGF*I concentra* tions showed a marked Variation when determined in three acromegalics orice monthly during three consecu^· tive months: saliva values ranged from 2.3 to 26.9 μ §/1, in contrast to serum values, which varied from 559.7 to 619.6 μβ/1.
The patients with active acromegaly had significantly higher salivary and serum IGF-I concentrations than the normals: 10.5 ± 5.69 vs. 5.4 ± 2.64 μg/l (p < 0.01) and 520 ± 98.8 vs. 176 ± 42.9 μ §/1 (ρ < 0.0001), respectively, s well s serum somatotropin concentrations: 15.4 ± 9.89 vs. 1.2 ± 1.02 μg/l (p < 0.0001). However, eight out of 17 (47.1%) active acromegalics had salivary IGF-I levels within the reference r nge. None of the active acromegalics had serum IGF-I or somatotropin within the reference r nge ( fig. 1 ).
In the group of healthy individuals and those with acromegaly, no significant correlation between salivary IGF-I and serum IGF4 or somatotropin was found. Nevertheless, in the combined group of healthy s bjects and active acromegalics (n = 30), a significant correlation between serum and salivary IGF-I was observed: r = 0.489, p < 0.01; rto correlation between salivary IGF-I and basal serum somatotropin concentrations was found. In five acromegalic patients before and after complete adenomectomy, serum IGF-I and somatotropin concentrations differed significantly (p < 0.005), in contrast to salivary IGF-I levels (p > 0.2) (tab. 1). Beside normal preoperative levels of salivary IGF-I, there was also a case of paradoxically increased salivary IGF-I concentration postoperatively.
Discussion
A sensitive RIA test for the determination of IGF-I concentrations in serum (after extraction) and saliva was designed. Within the same assay, serum and salivary IGF-I could be determined, making the evaluation of IGF-I levels in both samples more convenient.
Our results showed acromegalics to have significantly higher mean serum IGF-I and somatotropin concentrations and higher salivary IGF-I levels than the normal subjects. However, salivary IGF-I showed poor correlation with the disease activity; it was within the normal ränge in almost a half of the active acromegalics. Some patients had paradoxically low levels of salivary IGF-I, although they showed clear signs of disease activity, while serum IGF-I and somatotropin concentrations were well above the normal ränge. None of the active acromegalics had serum IGF-I or somatotropin concentration within the normal ränge. Measurerhent of sali- vary IGF-I levels postoperatively showed no advantage over the determination of serum IGF-I and somatotropin concentrations.
Costigan et al. (4) also found a statistically significant difference between normal subjects and active acromegalics for both serum and salivary IGF-I levels. Whereas the ratio of mean salivary IGF-I levels in their acromegalics and normal subjects was 7.5, in our study it was 1.9. The results with our RIA System showed serum IGF-I to be a much more reliable quantity in the evaluation of the disease activity than salivary IGF-I levels. Nevertheless, comparison of the levels of IGF-I in serum and saliva of normal subjects and acromegalic patients pointed to a significant positive linear correlation. Differences between these two studies could be due to the use of different Standards, antibodies and conditions for RIA, contributing to unavoidable variations in the concentrations of IGF-I in serum and saliva.
A disadvantage of saliva äs a sample may arise from the fact that it is an open System where the concentration of IGF-I may depend on the IGF-I content of the gland during salivation. A marked biological Variation, äs shown in this study, and the patient's hydration level (4) could further decrease the salivary IGF-I value in acromegalics. In contrast, serum is a defined System with a long half-life (several hours) of IGF-I (8) due to association with its binding proteins (3), and is less influenced by the patient's hydration condition. Finally, the liver may be a more appropriate target organ for the action of growth hormone than the salivary gland, which could be more liable to various undefined influences.
In conclusion, the measurement of IGF-I levels in saliva of acromegalics cannot be considered äs an additional, usefiil quantity for evaluation of the disease activity in acromegaly, because it does not adequately mirror the corresponding serum levels.
